Iron homeostasis is disrupted in multiple myeloma (MM), a difficult-to-cure plasma cell malignancy with 
Introduction
Iron is an essential element for almost every type of cell; it is involved in various biological processes such as haem synthesis, mitochondria respiratory, DNA synthesis, cell cycle et al (1) . Intracellular Iron homeostasis is strictly regulated in normal cells at the level of uptake, storage, export and even the microenvironment (2) . Dysregulation of iron homeostasis results in change of cell fate and promotes diseases such as cancer (3, 4) . Many types of cancer have alterations in iron metabolism resulting in increased intracellular iron levels which facilitate malignant cell growth and disease progression. For instance, iron enhances colorectal tumorigenesis in the presence of APC mutations by augmenting WNT signaling and downregulating E-cadherin (5) . Reduced iron export is another way that cancer cells use to increase concentration of iron besides increased iron uptake and decreased iron storage. Unlike multiple ways of iron uptake by different proteins such as TFRC (6) and Lipocalin 2 (7), FPN1 is the only known exporter of iron in vertebrates (8) . FPN1 encodes a multiple-transmembrane domain protein for the transfer of cellular iron to plasma, which regulates the exit of iron from enterocytes into the blood circulation (9) . It is expressed in many iron-exporting cells, including placental syncytiotrophoblasts, duodenal enterocytes, hepatocytes, and reticuloendothelial macrophages (10) . Mutations, resulting in loss-of-function of FPN1, cause hyperferritinemia and iron overload in macrophage or hepatocytes (11) .
Hepcidin, the physiological ligand of FPN1 (12) , inhibits iron export by inducing internalization and proteasome degradation of FPN1 protein (13) . Although regulation of iron by FPN1 has been well studied in iron homeostasis, the role of FPN1 in the context of cancer is just beginning to emerge. FPN1 is significantly down-regulated in breast cancer cells compared with their normal counterparts.
Consistent with the low levels of FPN1 expression, the breast cancer cells showed a markedly higher labile iron pool than the non-malignant breast epithelial (14) . Importantly, low expression of FPN1 was linked to poor prognosis in primary breast cancer samples using gene expression profiles (14) .
Multiple myeloma (MM) is a difficult-to-cure plasma cell malignancy the growth, survival and drug resistance of which is intimately tied to interactions with stromal cells including osteoclasts, osteoblasts and extracellular matrix proteins in the bone microenvironment (15) . The crosstalk between the MM cells and different cells of the BM microenvironment regulates survival and proliferation of MM cells and results in other pathological conditions such as bone destruction by osteoclasts (16) . It is very common that patients with MM present with anemia due to systemic alteration in iron metabolism (17) .
The limited iron availability resulting in impaired erythropoiesis is probably the main reason for myeloma-associated anemia (18) . Elevated IL-6 and bone morphogenetic proteins (BMPs) in the marrow of MM patients are the primary cytokines which induce high expression of hepcidin (19, 20) .
The myeloma cells also show increased requirement of iron due to a relatively high rate of proliferation and metabolism when compared to normal plasma cells (21) . In addition to suppressing osteoblastogenesis by secreting the WNT signaling inhibitor DKK1 (16) , myeloma cells also promote osteoclastogenesis by eliciting stroma cells to produce RANKL which is the major inducer of osteoclast differentiation from its macrophage precursors (22) . A recent study shows that activation of osteoclasts demands high iron uptake to facilitate mitochondrial biogenesis(23).
Here we explore the expression of FPN1 in different progression stages of MM and correlate FPN1 expression with patient outcome. We provide evidence that downregulation of FPN1 plays an important role in accelerating malignant cell growth and osteoclast differentiation. Our data indicate that therapeutics with ability of elevating expression of FPN1 might hold promising key of improving the outcome in MM.
Materials and Methods

Cell culture, drug treatment and cell growth
Human myeloma cell lines (ARP1, OCI-MY5 and their derivative cell lines ARP1-FPN1, OCI-MY5-FPN1, OCI-FPN1-STAT3c and OCI-MY5-MCL-1, and their relative controls) and murine myeloma cell lines (5TGM1 and 5TGM1 with inducible expression of FPN1) were cultured in RPMI 1640 medium (Invitrogen, Carlsbad, CA), supplemented with 10% heat-inactivated fetal bovine serum (FBS; Invitrogen, Carlsbad, CA), penicillin (100 IU/mL), and streptomycin (100 ʅg/mL) in a humidified incubator at 37°C and 5% CO 2 /95% air. The murine macrophage cells RAW264.7 were cultured in DMEM medium (Invitrogen, Carlsbad, CA) with the same supplements. Primary bone marrow mononuclear cells collected from wildtype C57B mice were cultured in the macrophage medium (Cell Biologics, Chicago, IL) with M-CSF (PeproTech, Rocky Hill, NJ)for 3 days with medium change every day. The attached cells were considered as BMM for the following osteoclast differentiation experiments induced by myeloma conditioned medium (5%) or RANKL (50 ng/ml plus 10 ng/ml M-CSF, PeproTech, Rocky Hill, NJ). For experiments, human myeloma cells were incubated with FeCl 3 , DFO and FAC (Sigma-Aldrich, St Louis, MO). Cell growth was counted by PestroBlue assay (Invitrogen, Carlsbad, CA) trypan-blue exclusion assay as reported (24) .
Clonogenic assay
Clonogenic growth was performed as previous reported (25) . Briefly, 10,000 myeloma cells were plated in 0.5 mL 0.33% agar/RPMI 1640 (Invitrogen, Carlsbad, CA) supplemented with 10% FBS. Cells were incubated (37°C, 5% CO 2 ) and fed with the same medium twice a week. One colony was defined if more than 40 cells were observed. Plates were imaged and colonies were enumerated using Image J software.
Plasmids and virus production
Human FPN1 coding sequence was purchased from OriGene and subcloned into lentiviral vector pWPI using PacI and XhoI sites. An EGFP-N1 vector with mouse FPN1 was provided by Dr. Ivana De Domenico.
The mouse FPN1 coding sequence was inserted to Age I and Mlu l sites of doxycycline inducible expression derivate from pTRIPZ from Dr. Dana Levasseur's lab (University of Iowa, Iowa City, IA). The constitutively active form of STAT3 and MCL-1 expression vectors were purchased from Addgene.
Lentivirus was produced in HEK293T cells using vsv-g and psPAX2 helper vectors (Addgene).
Mouse models
All mouse experiments were performed under protocols approved by the Institutional Animal Use and Care Committee of the University of Iowa. Human myeloma cells (1.5 X 10 6 cells in 100 ml PBS) were injected subcutaneously into the abdomen of NOD-Rag/null gamma mice. Tumor burdens were monitored by tumor volumes. In KaLwRij mouse model, 5TGM1 -FPN1 (1 X 10 6 cells in 100 ml PBS) were injected through tail vein. After 7 days, doxycycline (2 mg/ml, Sigma-Aldrich, St Louis, MO) was added to the drinking water (contains 5% sucrose) and dextran-iron (0.5 mg/kg, Sigma-Aldrich, St Louis, MO) was injected intraperitoneally twice a week. Mice were bled every week to harvest sera for detecting
IgG2b by ELISA assay according to manufactory's instruction (Bethyl Laboratories, Montgomery, TX).
Western blotting
Cell lysates were equally loaded onto 4-15% SDS-PAGE (Bio-Rad, Richmond, CA), electrophoresed, and transferred to enhanced chemiluminescence-nitrocellulose membranes (Bio-Rad, Richmond, CA). The membranes were stained with 0.2% Ponceau S red to ensure equal protein loading. After blocking with 5%
nonfat milk in Tris-buffered saline, the membranes were incubated with antibodies against FPN1 
Liable iron pool (LIP) assay
The cellular LIP was measured with fluorescent metallosensor calcein as described (14) . The SIH (salicylaldehyde isonicotinoyl hydrazone) used in the assay was synthesized by Dr. Zhendong Jin lab (University of Iowa, Iowa City, IA). (27, 28) . We also used 3 publicly available datasets for human MM microarrays to compare normal plasma cells and MM cells (GSE2658, GSE9782, GSE19784). The supervised cluster analysis was performed in statistical software R (Version2.6.2).
Flow cytometry
Statistical analyses
Unpaired T Test was used to evaluate the difference between 2 different Groups. In correlation of FPN1
and MCL-1 expression with disease progression, event-free survival and overall survival were measured using the Kaplan-Meier method, and the log-rank test was used for group comparison as previously reported (29) . A P value of less than 0.05 was considered statistically significant.
Results:
Low-expression of FPN1 is linked to poor survival in MM.
To evaluate iron regulation in multiple myeloma cells, we reanalyzed our previous gene expression profiling date containing 22 normal plasma cell samples (NPCs) and 351 newly diagnosed MMs from the Total Therapy 2 (TT2) cohort using the Affymetrix U133Plus 2 platform(30). Of the 61 signature genes related to iron metabolism (31) (131 probe sets), we identified 29 genes significantly dysregulated by comparison of NPC versus MM samples (Table S1 ; p < 0.005; ratio >= 1.5 fold). A supervised hierarchical cluster in Figure 1A showed clearly that a subset of MM patients have 18 genes down-regulated and 11
genes up-regulated in MM. These include iron importing genes, IREB2 and TFRC, and iron exporting gene, FPN1. We then correlated the expression of these 29 genes with patient outcome in the TT2 cohort, FPN1, the only vertebrate iron exporter, was found to be the top gene whose down-regulation in MM was associated with an inferior outcome (Table S. 1, overall survival (OS): p = 0.0032). Since FPN1 had a dysregulated expression and was associated with poor survival, we explored its functional role in MM.
We also evaluated the expression of FPN1 in sequential MM samples from the same patient, in the different genetic subgroups and in the different risk-related subtypes (27, 28) . 1B). We also found that expression of FPN1 had the lowest expression in the proliferation subgroup (PR), which is the subgroup with the poorest prognosis (p < 0.0001, Figure 1C ), and was significantly lower in the high-risk group compared with the low-risk group based on our 70-gene model (p = 0.013, Figure 1D ).
We performed survival analyses in three different data sets. Consistent with the low FPN1 expression in the aggressive MM subgroups, decreased FPN1 in the 351 TT2 cohort showed that about 60% of such cases showed short event-free survival (EFS) ( Figure 1E , p < 0.001) and also inferior overall survival (OS) (p < 0.001, Figure 1F ). The correlation of low FPN1 with inferior patient outcome was further validated in two other independent cohorts, including 270 newly diagnosed MM enrolled in the HOVON-65 clinical trial ( Figure 1G ) and 264 relapsed myeloma patients enrolled in the APEX phase 3 clinical trial ( Figure 1H ) (32) .
Restoring expression of FPN1 suppresses MM cell growth both in vitro and in vivo.
The altered iron gene expression signature strongly suggests that MM cells have abnormal iron Figure 4B ) and the highest expression levels were observed in the proliferaton group ( Figure 4C ) and in the high-risk group designated by the 70-gene model ( Figure 4D ). Consistent with the high MCL-1 expression in aggressive MM subgroups, high expression of MCL-1 was linked to an inferior outcome, significant for both event-free and overall survival in newly diagnosed MM patients ( Figure 4E , EFS p=0.048; Figure 4F , OS p=0.006). Furthermore, by combining FPN1 and MCL-1, we identified that MM patients with low expression of FPN1 and high expression of MCL-1 had the worst outcome ( Figure 4G , EFS p<0.001; Figure 4H , OS p<0.001).
The above data suggest that STAT3 and MCL-1 are likely involved in FPN1 signaling in MM. To test whether STAT3 or MCL-1 can rescue cell growth inhibition induced by high FPN1, a constitutively active form of STAT3 (STAT3c) and MCL-1 were transduced into OCI-MY5-FPN1 cells ( Figure S.1E and F) . As shown in Figure 4I , overexpression of STAT3c almost complete reversed cell growth inhibition in the presence of ectopic expression of FPN1. Overexpression of MCL-1 only partially recovered cell growth, indicating that STAT3 also activates other pathways than just MCL-1. As MCL-1 is the major factor involved in the survival of bone marrow plasma cells, we tested whether the STAT3-MCL-1 pathway would have an effect on the cell survival in the presence of high FPN1 levels. As shown in Figure 4J , overexpression of FPN1 sensitized MM cell to apoptotic stimuli, which was abrogated by overexpression of STAT3c or MCL-1.
FPN1 is downregulated inthe initial phases of myeloma cell-induced osteoclast differentiation.
Osteolytic bone disease is a frequent complication of multiple myeloma affecting up to 80% of patients (34) . It is widely known that FPN1 is highly expressed in normal macrophages which are the precursors of osteoclast (OCL) in bone marrow, we hypothesized that FPN1 had a major role in MM cell-induced OCL differentiation. The murine macrophage cells RAW264.7 and primary bone marrow macrophages (BMMs) from wild-type C57BL6 mice were cultured in the conditioned media collected from ARP1, OCI- Figure 5E ), which was very similar to the previously reported osteoclastogenesis inhibitory factor IRF8 (35) (Figure 5E ). Previous reports show that iron uptake coordinates with mitochondrial biogenesis orchestrated by PGC-1ɴ to induce osteoclastogenesis (23). Here we observed that significant upregulation of TFRC and PGC-1ɴ occurred at 48 hours after induction (Figure 5E ), indicating the downregulation of FPN1 preceded the changes of most critical driving factors (TFRC, PGC-1ɴ and NFATc1) (23, 36, 37) or markers (CTSK and TRAP of) osteoclastogenesis (38) , is an critical event of osteoclast differentiation ( Figure 5E ).
High FPN1 suppresses myeloma cell-induced osteoclast differentiation.
The early down-regulation of (1). In addition, the cancer cell itself also has dramatic changes in iron metabolism. The storage of intracellular iron into ferritin is often disrupted by oncogenes such as MYC or RAS, leading to increased availability of iron which promotes DNA synthesis and cell proliferation (41, 42) . Decreased iron export is relatively less well studied in the context of cancer cells.
In the present study, we systemically investigated, for the first time, the expression of iron gene signature using gene expression profiling in MM. We observed that iron metabolism in MM is strongly dysregulated by applying an iron signature to a clinical data set from a previously studied cohort of patients (30) . When compared to NPCs, MM cells are prone to up-regulate signals that maintain a high intracellular iron level. A marked reduction of the only known iron exporter FPN1 was observed in MM cells compared to NPCs. The lowest FPN1 levels were observed in the most aggressive subgroups of myeloma, which is consistent with previous reports that FPN1 is a strong and independent predictor of prognosis in breast cancer (14) .
Previous studies show that high hepcidin is responsible for myeloma associated anemia and is correlated with MM progression (43) . Unlike breast cancer cells, hepcidin expression is significantly decreased in MM cells compared to normal plasma cells (Table S. CAN-14-3804 production of hepcidin in liver in MM patients (19, 20) . Our data show that the decrease of FPN1 in MM cells happens at the transcription level. Therefore we think that hepcidin has only a minor effect on the regulation of FPN1 in MM cells. Elevated hepcidin may have more predominant role on other cells like in hepatocytes, duodenal enterocytes, RBCs and macrophages, which regulate systematic iron metabolism.
We found that FPN1 downregulates STAT3-MCL-1 signaling, one of the critical pathways of plasma cell growth and survival (44, 45) . Although JAK-STAT3 signaling is not required for hepcidin induced proteasome degradation of FPN1 (46) 
